Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integrated Diagnostics Announces $47M Funding

Published: Wednesday, April 30, 2014
Last Updated: Wednesday, April 30, 2014
Bookmark and Share
Company raises $30.25 million from the closing of its Series B and $17 million in non-dilutive debt financing provided by Life Sciences Alternative Funding LLC.

The financing round was led by Baird Capital and joined by Indi’s (Integrated Diagnostics') existing investors, InterWest Partners and the Wellcome Trust. Indi’s first product, Xpresys™ Lung, is a breakthrough, molecular diagnostic blood test developed to provide physicians with an objective tool to address a major medical dilemma—the management of indeterminate lung nodules. The mixed equity and debt investment will be used to further commercialize Xpresys, which launched in late 2013, and to develop additional proteomic blood tests using Indi’s technology platform.

“Indi’s Series B represents our investors and management’s belief Xpresys Lung has the potential to achieve blockbuster status,” said Albert A. Luderer, Ph.D., chief executive officer, Indi. “Xpresys Lung was designed to aid physicians in managing lung nodules— helping to eliminate unnecessary invasive procedures on benign conditions; enabling payers to improve outcomes and save millions of dollars in unnecessary procedures; and minimizing patient anxiety. We are very excited to welcome our new backers, Baird Capital and Life Sciences Alternative Funding LLC (LSAF). The partners at both firms have long track records of investing in medical diagnostics companies.”

As part of the financing, Michael Liang, Ph.D., partner with Baird Capital’s venture capital group, joins Indi’s board of directors. Indi also announced that Alexandria Venture Investments, the strategic venture arm of Alexandria Real Estate Equities, Inc., has joined the Series B as an investor.

“We are very pleased to help Indi take their early commercial success with Xpresys Lung to the next level,” said Liang. “Indi has taken their innovative proteomic technology and applied it to a massive unmet need: the high costs associated with over-diagnosing lung nodules. Their strategy is a perfect fit for Baird Capital’s focus on investing in companies who produce innovative technologies that address expanding market needs.”

Data from two studies supporting the technology behind Xpresys Lung were published in Science Translational Medicine on October 16, 2013. Click here to access the full study.

“We believe Xpresys Lung will play a significant role in helping physicians more effectively manage lung nodules—and Indi’s technology for blood-based diagnostics has the potential to become an important tool in multiple areas of health care,” said Steve DeNelsky, president, LSAF. “Our aim is to provide non-dilutive capital to outstanding commercial-stage life sciences companies in medical devices and diagnostics. We are delighted to play a role in Indi’s success.”

Today, it is estimated millions of pulmonary nodules are discovered each year; after traditional assessment protocols, which include biopsies and surgeries, most of these nodules are classified as benign. Xpresys Lung allows for the non-invasive assessment of pulmonary nodules in the 8-30 mm size range; traditionally, nodules of this size are associated with significant diagnostic uncertainty. Xpresys Lung provides physicians with objective information to identify nodules with a high probability of being benign, potentially reducing unnecessary invasive procedures that may be risky for the patient and costly to the healthcare system. In developing the test, researchers at Indi followed an innovative strategy: Xpresys Lung is designed only to assist physicians in identifying lung nodules likely to be benign, and is not intended to assist physicians with the identification of lung cancer.

The blood test measures the relative abundance of proteins from multiple pathways associated with lung cancer, using a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caltech and Integrated Diagnostics Researchers Receive Grand Challenges Point-of-Care Diagnostics Grant
The grant will be issued by Grand Challenges in Global Health, who seeks to engage creative minds across scientific disciplines to work on solutions that could lead to breakthrough advances for those in the developing world.
Monday, December 19, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
Researchers Can Control Genes Involved in Cancer
A new way to control the activity of a protein, that is often upregulated in cancer, has been discovered by Moffitt researchers through monoubiquitination mechanism.
Mitochondrial Role in Metastatic Cancer
Researchers have manipulated proteins, sourced from tumour cells, that are essential for maintaining tumour cells and in doing so, have significantly reduced the ability of cancer cells.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!